HC Wainwright Begins Coverage on Bionano Genomics (NASDAQ:BNGO)

HC Wainwright began coverage on shares of Bionano Genomics (NASDAQ:BNGO) in a research report released on Wednesday morning, Marketbeat reports. The firm issued a buy rating and a $10.00 target price on the stock. HC Wainwright also issued estimates for Bionano Genomics’ Q1 2025 earnings at ($3.49) EPS, Q2 2025 earnings at ($2.69) EPS, Q3 2025 earnings at ($2.62) EPS, Q4 2025 earnings at ($1.87) EPS, FY2025 earnings at ($10.26) EPS, Q1 2026 earnings at ($1.60) EPS, Q2 2026 earnings at ($1.33) EPS, Q3 2026 earnings at ($1.15) EPS, Q4 2026 earnings at ($1.12) EPS and FY2026 earnings at ($5.12) EPS.

Separately, Scotiabank boosted their target price on shares of Bionano Genomics from $1.00 to $4.00 and gave the company a “sector perform” rating in a research note on Wednesday, April 2nd.

Bionano Genomics Price Performance

Shares of NASDAQ:BNGO opened at $4.52 on Wednesday. The company has a market capitalization of $13.59 million, a P/E ratio of -0.03 and a beta of 2.08. The company’s 50-day moving average is $4.10 and its 200 day moving average is $11.66. The company has a debt-to-equity ratio of 0.07, a quick ratio of 0.99 and a current ratio of 1.43. Bionano Genomics has a fifty-two week low of $2.68 and a fifty-two week high of $72.60.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Carret Asset Management LLC raised its stake in Bionano Genomics by 39.9% in the 4th quarter. Carret Asset Management LLC now owns 119,000 shares of the company’s stock valued at $34,000 after acquiring an additional 33,945 shares during the period. XTX Topco Ltd purchased a new position in shares of Bionano Genomics in the fourth quarter worth about $45,000. Renaissance Technologies LLC bought a new stake in shares of Bionano Genomics in the fourth quarter valued at approximately $46,000. Jane Street Group LLC purchased a new stake in shares of Bionano Genomics during the 4th quarter valued at approximately $118,000. Finally, Geode Capital Management LLC lifted its stake in shares of Bionano Genomics by 13.0% during the 4th quarter. Geode Capital Management LLC now owns 997,676 shares of the company’s stock valued at $288,000 after buying an additional 114,822 shares in the last quarter. Hedge funds and other institutional investors own 11.35% of the company’s stock.

About Bionano Genomics

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.